Valneva SE (EPA:VLA)
France
· Delayed Price · Currency is EUR 3.708
-0.068 (-1.80%)
Feb 21, 2025, 5:35 PM CET
Valneva SE Revenue
Valneva SE had revenue of 45.82M EUR in the quarter ending September 30, 2024, with 20.36% growth. This brings the company's revenue in the last twelve months to 158.54M, down -28.98% year-over-year. In the year 2023, Valneva SE had annual revenue of 153.71M, down -57.46%.
Revenue (ttm)
158.54M
Revenue Growth
-28.98%
P/S Ratio
3.22
Revenue / Employee
234.52K
Employees
676
Market Cap
602.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 26.51B |
| Sanofi | 44.29B |
| Sartorius Stedim Biotech | 2.78B |
| bioMérieux | 3.81B |
| Eurofins Scientific SE | 6.95B |
| Ipsen | 3.57B |
| Virbac | 1.34B |
| emeis Société anonyme | 5.43B |
Valneva SE News
- 4 days ago - Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook - GlobeNewsWire
- 16 days ago - Valneva rises after U.K. approval of chikungunya vaccine - Seeking Alpha
- 17 days ago - Valneva Receives Marketing Authorization in the UK for the World's First Chikungunya Vaccine, IXCHIQ® - GlobeNewsWire
- 22 days ago - Valneva wins new U.S. contract for Japanese encephalitis vaccine, Ixiaro - Seeking Alpha
- 23 days ago - Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million - GlobeNewsWire
- 4 weeks ago - Valneva Is A 'Buy' As A First-Mover In Chikungunya - Seeking Alpha
- 4 weeks ago - Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision - GlobeNewsWire
- 4 weeks ago - Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot - Benzinga